bioMerieux ( (FR:BIM) ) just unveiled an announcement.
bioMérieux has received 510(k) authorization from the FDA for its VITEK® COMPACT PRO system, designed to enhance the identification of microorganisms and antibiograms in both clinical and industrial settings. This system aims to address the growing challenge of antibiotic resistance by providing rapid, accurate diagnostics, improving laboratory efficiency, and promoting the proper use of antibiotics. The VITEK® COMPACT PRO is set to launch globally in 2025, offering advanced ergonomics and automation to small and medium-sized laboratories, thus strengthening bioMérieux’s position as a leader in microbiology innovation.
More about bioMerieux
bioMérieux is a global leader in the field of in vitro diagnostics, specializing in automated identification and antibiogram systems. With over 60 years of experience, the company focuses on combating antibiotic resistance and ensuring the proper use of antibiotics through innovative microbiology solutions for clinical and industrial laboratories.
YTD Price Performance: 11.99%
Average Trading Volume: 43,108
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €13.52B
Find detailed analytics on BIM stock on TipRanks’ Stock Analysis page.